KL
RNTX

KCK Ltd’s Rein Therapeutics RNTX Stock Holding History

KCK Ltd’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$52.1K Hold
22,341
– – 0.34% 2
2025
Q2 		$249K Hold
22,341
– – 1.36% 2
2025
Q1 		$39.5K Hold
22,341
– – 0.38% 2
2024
Q4 		$51.4K Buy
+22,341
New +$67.7K 0.07% 3
2023
Q3 		$34K Hold
22,341
– – 0.05% 3
2023
Q2 		$40K Hold
22,341
– – 0.06% 3
2023
Q1 		$27.7K Hold
22,341
– – 0.04% 3
2022
Q4 		$52.9K Hold
22,341
– – 0.08% 3
2022
Q3 		$101K Sell
22,341
-10,000
-31% -$42.2K 0.2% 3
2022
Q2 		$168K Hold
32,341
– – 0.24% 4
2022
Q1 		$331K Hold
32,341
– – 0.32% 4
2021
Q4 		$362K Buy
+32,341
New +$500K 0.26% 4

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

KCK Ltd's RNTX Position: Q3 2025 in Review

KCK Ltd held its Rein Therapeutics (RNTX) position steady in Q3 2025 at 22,341 shares worth $52.1K. The position accounts for 0.34% of the portfolio, ranked #2.

KCK Ltd first reported a position in RNTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $362K in Q4 2021. 40 funds tracked by Wall St. Rank hold RNTX as of Q3 2025.

  • KCK Ltd held 22,341 shares of Rein Therapeutics worth $52.1K as of Q3 2025.
  • KCK Ltd left its Rein Therapeutics share count unchanged in Q3 2025.
  • Rein Therapeutics made up 0.34% of KCK Ltd's portfolio in Q3 2025, its #2 holding.
  • KCK Ltd first reported a position in Rein Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • KCK Ltd's Rein Therapeutics position peaked at $362K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2025.

Based on KCK Ltd's 13F filing for Q3 2025, filed 14 Oct 2025.